Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/23/2026

1. GOOGL
2. TSLA
3. TXN
4. NOW
5. AMD
6. GOOG
7. INTC
8. CSX
9. KNX
10. IBM

Go back to Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
(NASDAQ: HELP) Delayed: 7.73 -0.09 (1.15%)
Previous Close $7.82    52 Week High $ 
Open $7.78    52 Week Low $ 
Day High $8.16    P/E N/A 
Day Low $7.67    EPS $ 
Volume 988,927       

(NASDAQ: HELP) Delayed: 7.73 -0.09 (1.15%)
Previous Close $7.82    52 Week High $ 
Open $7.78    52 Week Low $ 
Day High $8.16    P/E N/A 
Day Low $7.67    EPS $ 
Volume 988,927